Aptamer selection and applications for breast cancer diagnostics and therapy

Journal of Nanobiotechnology

Review

Zhu Chen¹  Song Li¹  Qianqian Liu²  Keke Du²  Zhifei Wang²  Dandan Yang²  Mei Liu³  Bo Li⁴  Xiaocheng Yu⁴  Tong Yang⁴  Nongyue He⁵  Yan Deng⁵ 

[1] Economical Forest Cultivation and Utilization of 2011 Collaborative Innovation Center in Hunan Province, Hunan Key Laboratory of Green Chemistry and Application of Biological Nanotechnology, Hunan University of Technology, 412007, Zhuzhou, People’s Republic of China;School of Chemistry and Chemical Engineering, Southeast University, 211189, Nanjing, People’s Republic of China;School of Chemistry and Chemical Engineering, Southeast University, 211189, Nanjing, People’s Republic of China;State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, 210096, Nanjing, People’s Republic of China;State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, 210096, Nanjing, People’s Republic of China;State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, 210096, Nanjing, People’s Republic of China;Economical Forest Cultivation and Utilization of 2011 Collaborative Innovation Center in Hunan Province, Hunan Key Laboratory of Green Chemistry and Application of Biological Nanotechnology, Hunan University of Technology, 412007, Zhuzhou, People’s Republic of China;

关键词: Aptamer;    SELEX;    Breast cancer;    Diagnosis;    Targeted therapy;   

DOI  :  10.1186/s12951-017-0311-4

 received in 2017-08-06, accepted in 2017-10-24,  发布年份 2017

来源: Springer

【 摘 要 】

Aptamers are short non-coding, single-stranded oligonucleotides (RNA or DNA) developed through Systematic Evolution of Ligands by Exponential enrichment (SELEX) in vitro. Similar to antibodies, aptamers can bind to specific targets with high affinity, and are considered promising therapeutic agents as they have several advantages over antibodies, including high specificity, stability, and non-immunogenicity. Furthermore, aptamers can be produced at a low cost and easily modified, and are, therefore, called “chemical antibodies”. In the past years, a variety of aptamers specifically bound to both breast cancer biomarkers and cells had been selected. Besides, taking advantage of nanomaterials, there were a number of aptamer-nanomaterial conjugates been developed and widely investigated for diagnostics and targeted therapy of breast cancer. In this short review, we first present a systematical review of various aptamer selection methods. Then, various aptamer-based diagnostic and therapeutic strategies of breast cancer were provided. Finally, the current problems, challenges, and future perspectives in the field were thoroughly discussed.

【 授权许可】

CC BY   
© The Author(s) 2017